Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

BMS and Janssen’s antithrombotic granted FDA fast track designation

BMS and Janssen’s antithrombotic granted FDA fast track designation

Bristol Myers Squibb (BMS) and the Janssen Pharmaceutical Companies of Johnson &Johnson have announced that all three prospective antithrombotic indications for milvexian have been granted fast track designation by the US

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug Bristol Myers Squibb (BMS) has announced positive results from a phase 2 study evaluating its investigational antifibrotic treatment in patients with idiopathic pulmonary fibrosis (IPF).

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis Bristol Myers Squibb's (BMS) Sotyktu (deucravacitinib) has been authorised for use in Great Britain to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn Bristol Myers Squibb (BMS) and Tubulis have announced an agreement aimed at developing differentiated antibody-drug conjugates (ADCs) for solid tumours.

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis Bristol Myers Squibb's (BMS') plaque psoriasis treatment, Sotyktu (deucravacitinib), has been approved by the European Commission (EC) for adults with moderate-to-severe cases who are candidates for systemic therapy.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...